Michael Weiss, TG Therapeutics CEO
May 31, 2022 10:00 AM EDTUpdated 05:00 PM
R&D
FDA+

TG Ther­a­peu­tics gets 3-month punt from FDA for stand­alone BLA in af­ter­math of Ukoniq + ad­comm with­draw­al

Paul Schloesser

Associate Editor

Just over a month af­ter B-cell ma­lig­nan­cy and au­toim­mune-fo­cused biotech TG Ther­a­peu­tics with­drew its ap­pli­ca­tion for blood can­cer com­bo U2 one week be­fore an ad­comm …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times